Antibacterial and Anticancer Properties of Boswellia carteri Birdw. and Commiphora molmol Engl. Oleo-Resin Solvent Extractions


Pharmacognosy Communications,2016,6,3,120-136.
Published:March 2016
Type:Original Article

Antibacterial and Anticancer Properties of Boswellia carteri Birdw. and Commiphora molmol Engl. Oleo-Resin Solvent Extractions

Jiayu Zhang,1,2 Isaac Biggs,1,3 Joseph Sirdaarta,1,3 Alan White,1 Ian Edwin Cock,1,3*

1School of Natural Sciences, Griffith University, Brisbane, AUSTRALIA

2School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, CHINA

3Environmental Futures Research Institute, Griffith University, Brisbane, AUSTRALIA



Background: Boswellia carteri Birdw. (frankincense) and Commiphora molmol Engl. (myrrh) oleo-resins  have traditionally been used for the growth inhibition of bacteria associated with skin diseases, urinary tract infections, respiratory infections, wound healing, dental disease and gastrointestinal disorders. Despite this, many bacterial pathogens are yet to be screened for susceptibility to frankincense and myrrh extracts. This study was undertaken to test extracts prepared from frankincense and myrrholeo-resins for the ability to inhibit microbial and cancer cell growth. Materials and Methods: Frankincense and myrrhresins were extracted and tested for antimicrobial activity using modified disc diffusion and MIC methods. Inhibitory activity against CaCo2 and HeLa cancer cell lines was evaluated using colorimetric cell proliferation assays. Toxicity was evaluated using an Artemia franciscana nauplii bioassay. The most promising inhibitory extracts were investigated using non-targeted GC-MS head space analysis (with screening against a compound database) for the identification and characterisation of individual components in the crude plant extracts. Results: The frankincense and myrrh extracts displayed broad spectrum antibacterial activity, inhibiting the growth of all of the bacteria screened against. The frankincense extracts were generally more potent growth inhibitors than were the corresponding myrrh extracts. The growth inhibition of the methanolic, ethyl acetate and hexane frankincense extracts against Salmonella salford was particularly noteworthy, with MIC values of 462, 258 and 293 µg/mL respectively. The frankincense and myrrh extracts were both approximately equally effective against gram positive and gram negative bacteria. The majority of the extracts also proved effective at blocking the proliferation of the colorectal cancer cell line CaCo2 and HeLa cervical cancer cell growth, although the aqueous and ethyl acetate frankincense extracts generally had the greatest efficacy (IC50 values 1600-1900 µg/mL). All extracts were non-toxic, with LC50 values substantially > 1000 µg/mL. Conclusion: These studies validate traditional usage of frankincense and myrrh in the treatment of several bacterial illnesses and some cancers, and indicate that they are safe for therapeutic usage.

Founded:  In 2004, as the PHCOG.NET – a non-profit private organization dedicated to Natural Products Research leading to develop promising drugs. Our main mission is to make information on herbal drug research readily available in different formats to suit the individual needs.

Pharmacognosy Communications [Phcog Commn.] is a new quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the  publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.

The journal aims to cater the latest outstanding developments in the field of pharmacognosy and natural products and drug design covering but not limited to the following topics:

  • Pharmacognosy and pharmacognistic investigations
  • Research based ethnopharmacological evaluations
  • Biological evaluation of crude extracts, essential oils and pure isolates
  • Natural product discovery and evaluation
  • Mechanistic studies
  • Method and technique development and evaluation
  • Isolation, identification and structural elucidation of natural products
  • Synthesis and transformation studies

Distinctions:  The most widely read, cited, and known Pharmacognosy Communications and website is well browsed with all the articles published. More than 20,000 readers in nearly every country in the world each month

Aim and Scope | Editorial Board | Indexed & Abstracted | Instruction to Authors | Manuscript Submission & Charges

Subjects Covered : Natural Products, Pharmacognosy, Phytochemistry, Marine Pharmacognosy and Zoo Pharmacognosy
ISSN :2249-0159 (Print) ; 2249-0167 (Online) Frequency : Quarterly Rapid at a time publication (4 issues/year)

Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online  publication is 45 days.
Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.